Genomic Precision

 A SeraCare blog focused on precision medicine and advanced clinical diagnostics

Accelerating Liquid Biopsy Assay Development

Session Summary from Next Generation Dx Summit 2017

Posted by Sam Blier on Sep 8, 2017 11:15:00 AM

At the 2017 Next Generation Dx Summit in Washington, DC, our CSO, Russell Garlick, PhD, presented a workshop on accelerating liquid biopsy assay development. He has worked closely with a variety of groups in the liquid biopsy space that are developing and validating circulating tumor DNA (ctDNA) assays. He highlighted some common challenges facing the field, and explained how SeraCare has been using these collaborations to develop QC tools specifically for ensuring the robustness of these cutting-edge tests.

Read More

Topics: ctDNA, liquid biopsy, assay development, circulating tumor DNA reference Materials, circulating cell-free DNA, biosynthetic reference materials, assay performance, 2017 Next Generation Dx Summit

How Many Target Copies Are Present in Your Plasma DNA Sample?

A 0.1% measurement requires a reasonable amount of input material

Posted by Dale Yuzuki on Jun 15, 2017 1:30:00 PM

The field of circulating tumor DNA analysis (ctDNA, also sometimes called in a larger context “liquid biopsy”) holds great promise for monitoring response to cancer treatment, assisting therapeutic choice, monitoring recurrence, and for pre-cancer screening. As such there is a great amount of assay development and ongoing clinical trials; at ClinicalTrials.gov searching for the term "Circulating DNA" you can find over 180 open clinical trials for a wide range of tumor types and interventions.

Read More

Topics: Cancer, Circulating Tumor DNA, ctDNA, liquid biopsy, plasma DNA Sample, ccfDNA, assay development

 
 

Subscribe for Updates

Categories

see all